Regulatory

Regulatory  ·  Weekly Digest - 07 March to 13 March 2026
Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

Weekly Digest – March 2026 Weekly Digest – March 2026 9 March 2026: Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer AstraZeneca and Daiichi Sankyo announced that the U.S. FDA has […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 07 March to 13 March 2026
Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Weekly Digest – March 2026 Weekly Digest – March 2026 09 March 2026: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma Oncopeptides announced that it has secured fast-track designation in Norway for a planned Window-of-Opportunity clinical study evaluating a […]

by Sandhya Ramalingam

Continue Reading